Sage Journals: Discover world-class research

Retricted access

Research article

First published 2021-4

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

Chiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2024-2

Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

Nicole Bou Rjeily, Kathryn C Fitzgerald, Ellen M Mowry

Multiple Sclerosis Journal

Open access

Research article

First published 2022-11

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

Magnus Johnsson, Helen H Farman, Kaj Blennow [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2024-6

Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis

Delania Meng, Rosaria Sacco, Giulio Disanto [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2023-2

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

John Foley, Kuangnan Xiong, Tammy Hoyt [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2024-6

Extended interval dosing with ocrelizumab in multiple sclerosis

Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-1

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis

Eileen J. McManus, Karen M. Clark, Christopher Frampton [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2026-1

Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis

Mahmoud Elkhooly, Rhea Jacob, Torge Rempe

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Free access

Research article

First published 2014-9

Extended interval dosing of natalizumab: a two-center,7-year experience

Roberto Bomprezzi, Siddharama Pawate

Therapeutic Advances in Neurological Disorders

Open access

Review article

First published 2022-10

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience

Julian Perneczky, Johann Sellner

Journal of Central Nervous System Disease

Search results